Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: John Curtis who wrote (1642)	4/7/2001 3:52:58 PM
From: Jibacoa	Respond to of 2344

<<I've lived with this reality for 7 years or so. I can live with it for another year or so, simply because their product line has some magnificent promise...> John: I have also lived with BIOM (previously BIOMF)as well as with VLNC for some time.My wife refers to those as "the vaccine company " and "the battery company" when she reminds me that I have been following them "for a few years before Andrew" (the hurricane that we had here in South FL several years ago).<g> I have no regrets since my profits in both companies over the years (specially last year) have been substantial.<g> Regarding BIOM, as you stated in this thread's opening remarks: <<In one part of two parallel trials(Phase II), patients who received the vaccine had a median survival of 26.6 months compared with 9.2 months for matched patients in a retrospective control group.>> <<The Phase III trial will ultimately involve 900 patients in approximately 75 sites worldwide. They expect to have all 900 patients logged(filled) and beginning the trial by next summer(year 2000). If all goes well then the first interim analysis of data comes out about six months after the trial fills. Based on Phase I & II results the bulls on this thread think this first interium analysis will vouchsafe earlier results, moving BIOM closer to FDA, and international, approvals for one of the first cancer vaccines by any bio-tech company in the industry.>> The enrollment is now complete and surpassed the 1000 mark. News about a new "partner" are expected soon. BIOM's other products like its BLP25 vaccine for lung cancer, which is encapsulated in a liposomal delivery system, as well as their Liposomal IL-2 which can be used combined with patient-specific tumor antigens to produce their Liposomal Idiotypic Vaccine, all look promising. They recently announced that they were issued patent number 6,207,170, entitled "Patient- specific white blood cell malignancy vaccine from membrane-proteoliposomes". The patent describes a new composition of matter and a cost-effective method for treating patients with an autologous vaccine. Biomira received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase Ib trial in patients with B-Cell lymphoma utilizing this vaccine approach. This trial will be conducted at the U.S. National Cancer Institute, as well as two cancer centers in New Jersey. Bottom line: I think BIOM's prospects are good, and although I already have made substantial profits with it, I expect to have even more in a not too distant future.<g> RAGL Bernard